1. Introduction {#sec1-cells-09-00749}
===============

Telomeres and their associated shelterin complex are located at chromosomal ends. Telomeres are tandem repeats of TTAGGG up to 15 kb long in humans. Together, telomeres and the shelterin complex protect chromosomal ends and preserve genomic DNA integrity \[[@B1-cells-09-00749],[@B2-cells-09-00749],[@B3-cells-09-00749],[@B4-cells-09-00749]\]. Telomeres are shortened with each cell division. When telomere length falls below a critical threshold, cells become replicatively senescent and undergo apoptosis \[[@B5-cells-09-00749]\]. Cancer cells circumvent replicative telomere shortening by stabilizing them \[[@B6-cells-09-00749]\] through one of two mechanisms: reactivation of telomerase, the enzyme that extends telomeres (85--90% of cancers) \[[@B7-cells-09-00749],[@B8-cells-09-00749],[@B9-cells-09-00749],[@B10-cells-09-00749]\], or homologous recombination between sister chromatids, a phenomenon termed alternative lengthening of telomeres (ALT) (3--10% of cancers) \[[@B10-cells-09-00749],[@B11-cells-09-00749],[@B12-cells-09-00749]\]. Telomerase is a ribonuclear holoenzyme composed of an RNA template (TERC) and a reverse transcriptase catalytic subunit (TERT) \[[@B1-cells-09-00749],[@B2-cells-09-00749],[@B3-cells-09-00749],[@B4-cells-09-00749],[@B13-cells-09-00749]\]. TERT is silent in most somatic cells, and is reactivated in cancer cells, endowing them with unrestricted proliferation capacity \[[@B6-cells-09-00749],[@B14-cells-09-00749],[@B15-cells-09-00749],[@B16-cells-09-00749]\].

Although TERT activity is regulated principally at the transcriptional level (reviewed in References \[[@B3-cells-09-00749],[@B4-cells-09-00749],[@B9-cells-09-00749],[@B17-cells-09-00749],[@B18-cells-09-00749],[@B19-cells-09-00749],[@B20-cells-09-00749],[@B21-cells-09-00749],[@B22-cells-09-00749]\]), it may also be regulated through splicing \[[@B23-cells-09-00749],[@B24-cells-09-00749]\], post-translational modifications, or intracellular trafficking \[[@B25-cells-09-00749],[@B26-cells-09-00749],[@B27-cells-09-00749],[@B28-cells-09-00749]\]. The *TERT* promoter (*TERTp*) contains binding sites for numerous transcriptional activators including Sp-1, c-Myc, Hypoxia Induced Factor (HIF), AP-2, β-catenin, NF-κB, E-twenty-six (Ets)/ternary complex factors (TCF) family members, and transcriptional repressors (Wilms' tumor (WT1), TP53, Nuclear Transcription Factor, X-Box Binding (NFX-1), Mad-1 and CCCTC binding factor (CTCF)) \[[@B3-cells-09-00749],[@B4-cells-09-00749],[@B9-cells-09-00749],[@B17-cells-09-00749],[@B18-cells-09-00749],[@B19-cells-09-00749],[@B20-cells-09-00749],[@B21-cells-09-00749],[@B29-cells-09-00749]\]. *TERT* expression can be reactivated by copy number variants (CNV), *TERT* or *TERTp* structural variants, chromosomal rearrangements juxtaposing *TERTp* to enhancer elements, cellular and viral oncogenes such as Hepatitis B virus (HBV) X protein (HBx) or high-risk Human papillomavirus (HPV)16 and HPV18 E6 oncoprotein, and, last but not least, mutations within *TERTp* (31% of TERT-expressing cancers) ([Figure 1](#cells-09-00749-f001){ref-type="fig"}A) \[[@B10-cells-09-00749],[@B30-cells-09-00749],[@B31-cells-09-00749],[@B32-cells-09-00749],[@B33-cells-09-00749],[@B34-cells-09-00749],[@B35-cells-09-00749],[@B36-cells-09-00749],[@B37-cells-09-00749],[@B38-cells-09-00749]\] (reviewed in \[[@B3-cells-09-00749],[@B4-cells-09-00749],[@B9-cells-09-00749],[@B18-cells-09-00749],[@B19-cells-09-00749],[@B20-cells-09-00749],[@B39-cells-09-00749]\]). Increased *TERTp* methylation is typically recorded in \>50% of TERT-expressing tumors and cell lines \[[@B10-cells-09-00749],[@B40-cells-09-00749],[@B41-cells-09-00749],[@B42-cells-09-00749],[@B43-cells-09-00749],[@B44-cells-09-00749],[@B45-cells-09-00749],[@B46-cells-09-00749],[@B47-cells-09-00749]\]. Epigenetic regulation of *TERTp* is based on altered methylation patterns of specific regions. Hypomethylation of the region between −200 and −100 from the Translational Start site (TSS), encompassing the core promoter, enables binding of c-Myc and Sp-1, thus reactivating transcription. In contrast, the region spanning exon 1 (positions +1 to ±100 from the TSS) contains a binding site for the DNA insulator CTCF. Hypermethylation of this region disrupts binding of CTCF and therefore allows *TERT* transcription \[[@B41-cells-09-00749],[@B42-cells-09-00749],[@B43-cells-09-00749],[@B44-cells-09-00749]\]. Similarly, the region between −600 and −200 from the TSS contains a second CTCF binding site and is partially hypermethylated in TERT-expressing cells \[[@B41-cells-09-00749],[@B42-cells-09-00749],[@B43-cells-09-00749],[@B44-cells-09-00749]\]. The transcriptional control of *TERT* has been comprehensively reviewed recently \[[@B3-cells-09-00749],[@B4-cells-09-00749],[@B9-cells-09-00749],[@B18-cells-09-00749],[@B19-cells-09-00749],[@B20-cells-09-00749],[@B21-cells-09-00749],[@B22-cells-09-00749],[@B29-cells-09-00749],[@B48-cells-09-00749]\] and, as such, is beyond the scope of this review. In this review, we focused on the distribution and exclusiveness of *TERTp* mutations.

2. Telomerase Reverse Transcriptase Promoter (*TERTp*) Mutations {#sec2-cells-09-00749}
================================================================

*TERTp* mutations were first described in congenital and sporadic melanoma in 2013 \[[@B49-cells-09-00749],[@B50-cells-09-00749]\]. Subsequent large-scale cohort studies together with seminal mechanistic studies both ascertained the *TERTp* mutation prevalence in many other forms of cancer and characterized their mode of action.

The two main *TERTp* mutations are located at positions 1,295,228 and 1,295,250 on Chromosome 5, and generate C to T transitions. They are located 124 and 146 base pairs upstream from the *TERTp* TSS ([Figure 1](#cells-09-00749-f001){ref-type="fig"}B). Less frequent tandem mutations −125/−124 CC\>TT and −139/−138 CC\>TT have been reported in cutaneous tumors ([Table 1](#cells-09-00749-t001){ref-type="table"}) \[[@B49-cells-09-00749],[@B51-cells-09-00749]\]. While these are somatic mutations, a germline mutation at position −57A\>C from the TSS has been identified in familial melanomas and showed similar effects \[[@B49-cells-09-00749]\]. All of these mutations have similar effects, increasing TERT expression \~2--6 fold as measured through qRT-PCR, immunohistochemistry, TRAP, or reporter vectors in numerous cancer types, as outlined in [Table 1](#cells-09-00749-t001){ref-type="table"} \[[@B37-cells-09-00749],[@B50-cells-09-00749],[@B52-cells-09-00749],[@B53-cells-09-00749],[@B54-cells-09-00749],[@B55-cells-09-00749],[@B56-cells-09-00749],[@B57-cells-09-00749],[@B58-cells-09-00749],[@B59-cells-09-00749],[@B60-cells-09-00749],[@B61-cells-09-00749],[@B62-cells-09-00749],[@B63-cells-09-00749],[@B64-cells-09-00749],[@B65-cells-09-00749]\]. This increased TERT expression maintains self-renewal potential and telomeres in both stem cells and terminally differentiated bladder cells, indicating that these mutations are sufficient to immortalize cells \[[@B66-cells-09-00749],[@B67-cells-09-00749]\].

All of these *TERTp* mutations (at positions −146, −124, −57, and −139/−138) create novel Ets/TCF transcription factor binding sites. The Ets/TCF transcription factors bind to GGAA motifs (or TTCC on the opposite strand). The 30 members of the Ets/TCF-family transcription factors are important contributors to oncogenesis and include Ets-1, Ets-2, and GA binding protein (GABP) \[[@B68-cells-09-00749]\]. So far, GABP has been reported to selectively bind the −124 C\>T and −146 C\>T mutations in GBM, melanoma, and urothelial bladder cancer cell lines \[[@B69-cells-09-00749],[@B70-cells-09-00749],[@B71-cells-09-00749]\]. Unlike the other Ets/TCF family transcription factors, GABP is an obligate dimer of GABPA and GABPB dimers. It binds two nearby in-phase GGAA sites \[[@B68-cells-09-00749],[@B72-cells-09-00749],[@B73-cells-09-00749],[@B74-cells-09-00749]\] positioned 1, 2, or *n* helical turns away from each other \[[@B69-cells-09-00749]\], or brought close together by DNA looping \[[@B70-cells-09-00749]\]. *TERTp* mutations are associated with epigenetically active chromatin \[[@B54-cells-09-00749],[@B69-cells-09-00749],[@B75-cells-09-00749],[@B76-cells-09-00749]\]. Intriguingly, whereas methylation of wild-type (wt) *TERT* promoter is associated with TERT expression \[[@B10-cells-09-00749],[@B43-cells-09-00749],[@B44-cells-09-00749]\], *TERTp* mutations are associated with decreased *TERTp* methylation \[[@B76-cells-09-00749]\]. The −146 C\>T mutation was also shown to bind the non-canonical NF-κB-p52 and Ets-1/2 \[[@B59-cells-09-00749]\].

*TERTp* mutations have been recorded in a wide range of solid cancers. They are present in primary gliomas and glioblastoma multiforme (GBM), oligodendrogliomas and astrocytomas \[[@B10-cells-09-00749],[@B40-cells-09-00749],[@B52-cells-09-00749],[@B53-cells-09-00749],[@B54-cells-09-00749],[@B57-cells-09-00749],[@B58-cells-09-00749],[@B60-cells-09-00749],[@B64-cells-09-00749],[@B65-cells-09-00749],[@B77-cells-09-00749],[@B78-cells-09-00749],[@B79-cells-09-00749],[@B80-cells-09-00749],[@B81-cells-09-00749],[@B82-cells-09-00749],[@B83-cells-09-00749],[@B84-cells-09-00749],[@B85-cells-09-00749],[@B86-cells-09-00749]\], melanomas, cutaneous basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) \[[@B49-cells-09-00749],[@B50-cells-09-00749],[@B51-cells-09-00749],[@B52-cells-09-00749],[@B55-cells-09-00749],[@B87-cells-09-00749],[@B88-cells-09-00749],[@B89-cells-09-00749],[@B90-cells-09-00749],[@B91-cells-09-00749]\], myxoid liposarcomas \[[@B77-cells-09-00749]\], urothelial bladder carcinoma \[[@B50-cells-09-00749],[@B57-cells-09-00749],[@B78-cells-09-00749],[@B92-cells-09-00749],[@B93-cells-09-00749],[@B94-cells-09-00749]\], hepatocellular carcinoma (HCC) \[[@B50-cells-09-00749],[@B57-cells-09-00749],[@B62-cells-09-00749],[@B95-cells-09-00749],[@B96-cells-09-00749],[@B97-cells-09-00749]\], and thyroid cancers \[[@B98-cells-09-00749],[@B99-cells-09-00749],[@B100-cells-09-00749],[@B101-cells-09-00749],[@B102-cells-09-00749],[@B103-cells-09-00749],[@B104-cells-09-00749],[@B105-cells-09-00749],[@B106-cells-09-00749]\], as well as oral and cervical SCC \[[@B36-cells-09-00749],[@B37-cells-09-00749],[@B57-cells-09-00749]\] ([Table 1](#cells-09-00749-t001){ref-type="table"}). Furthermore, they were consistently found in tumor cell lines derived from these malignancies \[[@B37-cells-09-00749],[@B50-cells-09-00749],[@B52-cells-09-00749],[@B54-cells-09-00749],[@B58-cells-09-00749],[@B62-cells-09-00749],[@B97-cells-09-00749],[@B100-cells-09-00749],[@B107-cells-09-00749],[@B108-cells-09-00749]\]. *TERTp* mutations often arise in tissues with low rates of self-renewal (brain, thyroid) \[[@B77-cells-09-00749]\], where they provide an immediate competitive advantage to cells that acquire them. Conversely, they appear to be infrequent (\<15%) in hematopoietic, lymphoid, or gastrointestinal malignancies. These are from compartments with high cellular turnover and intrinsic telomerase activity. Here, the endogenously elevated TERT levels likely render *TERTp* mutations neutral \[[@B3-cells-09-00749],[@B38-cells-09-00749],[@B57-cells-09-00749],[@B77-cells-09-00749],[@B109-cells-09-00749]\].

3. Cancer Distribution of *TERTp* Mutations {#sec3-cells-09-00749}
===========================================

The clinicopathological association of *TERTp* mutations is cancer-dependent. It is a consideration for fine tumor stratification and orientation of patients towards personalized treatments, and provides insight into the process of cellular transformation.

3.1. Gliomas and Glioblastoma (GBM) {#sec3dot1-cells-09-00749}
-----------------------------------

GBM are WHO Grade IV tumors of the central nervous system (CNS). Primary GBM evolve rapidly without prior low-grade lesions, while secondary GBM progress slowly from diffuse or anaplastic astrocytoma and oligodendroglioma (WHO Grade II and III). Primary and secondary GBM differ genetically more than histologically. The 2016 WHO classification of CNS tumors is based on "integrated diagnosis" including histology and isocitrate dehydrogenase (*IDH*)-*1/2* mutations (a biomarker for secondary GBM), and the presence of the 1p/19q codeletion (a marker for oligodendroglioma) \[[@B110-cells-09-00749]\]. *TERTp* mutations are relatively rare in diffuse (17.7%, range 10--19%) and anaplastic astrocytomas (24.7%, range 10--62.5%), as well as in *IDH*-mutated gliomas and secondary GBM (\~28%). Their prevalence is highest (64.7%, range 45--88.6%) in oligodendrogliomas (where they coexist with the 1p/19q full deletion \[[@B53-cells-09-00749]\]) and in primary GBM (68%, range 44--100%) ([Table 1](#cells-09-00749-t001){ref-type="table"}) \[[@B38-cells-09-00749],[@B52-cells-09-00749],[@B53-cells-09-00749],[@B65-cells-09-00749],[@B77-cells-09-00749],[@B80-cells-09-00749],[@B81-cells-09-00749],[@B84-cells-09-00749],[@B85-cells-09-00749],[@B111-cells-09-00749]\]. They tend to be found mainly in samples with epidermal growth factor receptor (*EGFR*) amplification, an early feature of primary GBM, \[[@B64-cells-09-00749],[@B77-cells-09-00749],[@B111-cells-09-00749]\]. Conversely, they appear to be mutually exclusive with mutations in α-thalassemia/mental retardation syndrome X-linked (*ATRX*) and Death Domain Associated Protein (*DAXX*) \[[@B38-cells-09-00749],[@B65-cells-09-00749],[@B77-cells-09-00749],[@B79-cells-09-00749],[@B80-cells-09-00749],[@B110-cells-09-00749],[@B111-cells-09-00749],[@B112-cells-09-00749]\], two telomere-binding proteins mutated in ALT \[[@B11-cells-09-00749],[@B12-cells-09-00749]\].

*TERTp* mutations are independently associated with older age, late clinical stage, poor prognosis, and shorter overall survival (OS) in GBM/glioma and *IDH*-wt astrocytoma patients. The presence of *TERTp* mutations alone is associated with a worse prognosis than *TERTp* mutations together with *IDH*-mutations \[[@B4-cells-09-00749],[@B60-cells-09-00749],[@B64-cells-09-00749],[@B65-cells-09-00749],[@B77-cells-09-00749],[@B79-cells-09-00749],[@B80-cells-09-00749],[@B81-cells-09-00749],[@B84-cells-09-00749],[@B85-cells-09-00749],[@B112-cells-09-00749]\]. Conversely, GBM patients with ALT and no *TERTp* mutations have longer OS than patients with *TERTp* mutations only \[[@B77-cells-09-00749],[@B112-cells-09-00749],[@B113-cells-09-00749]\]. In terms of treatment, Grade II and III *IDH*-wt CNS tumors generally respond to adjuvant radiation and chemotherapy with temozolomide (TMZ). However, the presence of *TERTp* mutations decreases sensitivity to genotoxic therapies. It has therefore been proposed to use *TERTp* mutations to further stratify *IDH*-wt Grade II and III gliomas into subgroups to orient treatment \[[@B60-cells-09-00749],[@B81-cells-09-00749],[@B114-cells-09-00749]\].

3.2. Melanoma and Non-Melanoma Skin Carcinoma {#sec3dot2-cells-09-00749}
---------------------------------------------

In patients with primary melanoma, *TERTp* mutations have been reported in 39.2% (range 22--71%) of tumors. They arise progressively in sun-exposed sites and have been attributed to UV radiation. They are associated with increased patient age, distal metastases, poor outcome, and compromised OS and disease-free survival (DFS) \[[@B49-cells-09-00749],[@B50-cells-09-00749],[@B51-cells-09-00749],[@B52-cells-09-00749],[@B88-cells-09-00749],[@B89-cells-09-00749],[@B115-cells-09-00749]\]. In \~50% of cases, they are associated with mutations in *BRAF*/*NRAS* \[[@B49-cells-09-00749],[@B52-cells-09-00749],[@B88-cells-09-00749],[@B89-cells-09-00749],[@B91-cells-09-00749],[@B116-cells-09-00749]\], influencing OS in the following order: *TERTp^mut^*+*BRAF*/*NRAS^mut^*\<*TERTp^mut^*\~*BRAF*/*NRAS^mut^*\<*TERTp*-wt+*BRAF*/*NRAS*-wt \[[@B56-cells-09-00749]\].

Consistent with their UV-induced origin in skin cancers, *TERTp* mutations are also highly prevalent at sun-exposed sites in non-melanoma squamous cell (50%) and basal cell carcinomas (46.2%, range 38--74%), the most common skin tumor \[[@B55-cells-09-00749],[@B89-cells-09-00749],[@B90-cells-09-00749]\]. *TERTp* mutations display unique features in melanoma and non-melanoma cancers. First, −146 C\>T and −124 C\>T occur with similar frequencies in contrast to all other cancers, where −124 C\>T is by far the most prevalent mutation ([Table 1](#cells-09-00749-t001){ref-type="table"}). Second, −139/−138 CC\>TT and −125/−124 CC\>TT tandem mutations are often reported. Third, *TERTp* mutations were detected in 9/10 melanomas with ALT in one study \[[@B117-cells-09-00749]\] and together (−124 C\>T + −146 C\>T) in two patients with BCC in another study \[[@B89-cells-09-00749]\], indicating that more than one telomere maintenance mechanism can, unusually, coexist in skin cancers.

3.3. Urothelial Bladder Cancer {#sec3dot3-cells-09-00749}
------------------------------

*TERTp* mutations have been detected in 64.6% (range 29.5--100%) of urothelial bladder and upper urinary tract cancers. They are the most common somatic lesions in this cancer type \[[@B52-cells-09-00749],[@B57-cells-09-00749],[@B61-cells-09-00749],[@B77-cells-09-00749],[@B92-cells-09-00749],[@B94-cells-09-00749],[@B118-cells-09-00749],[@B119-cells-09-00749]\]. They have been associated with reduced survival, disease recurrence, and distal metastases \[[@B61-cells-09-00749],[@B118-cells-09-00749],[@B119-cells-09-00749]\], although there appears to be no difference between early- and late-stage patients \[[@B52-cells-09-00749],[@B94-cells-09-00749]\].

3.4. Thyroid {#sec3dot4-cells-09-00749}
------------

Among thyroid cancers, *TERTp* mutations have been reported mainly in follicular-cell-derived thyroid malignancies (papillary thyroid carcinoma (PTC): 13.4%, range 4.1--37.7%; follicular thyroid carcinoma (FTC): 13.9%, range 5.9--66.7%; poorly differentiated thyroid carcinoma (PDTC): 43.7%, range 21--51.7%; and anaplastic thyroid carcinomas (ATC): 39.7%, range 13--50%). The presence of *TERTp* mutations is significantly associated with increased age, tumor size and stage, distal metastases, tumor recurrence, and shorter OS and DFS in PTC and FTC. Their prevalence increases from differentiated PTC and FTC to the more aggressive poorly differentiated ATC ([Table 1](#cells-09-00749-t001){ref-type="table"}) \[[@B98-cells-09-00749],[@B99-cells-09-00749],[@B100-cells-09-00749],[@B101-cells-09-00749],[@B102-cells-09-00749],[@B103-cells-09-00749],[@B104-cells-09-00749],[@B105-cells-09-00749],[@B106-cells-09-00749]\]. The association of TERTp mutations with the common *BRAF*-V600E mutation is a powerful predictor of poor OS and DFS \[[@B52-cells-09-00749],[@B98-cells-09-00749],[@B99-cells-09-00749],[@B104-cells-09-00749],[@B105-cells-09-00749],[@B106-cells-09-00749],[@B108-cells-09-00749]\]. As in glioma, *TERTp* mutations compromise the outcome of radioiodine therapy \[[@B101-cells-09-00749],[@B105-cells-09-00749]\].

3.5. Hepatocellular Carcinoma (HCC) {#sec3dot5-cells-09-00749}
-----------------------------------

*TERTp* mutations are an early event in hepatocellular tumorigenesis \[[@B57-cells-09-00749],[@B62-cells-09-00749],[@B77-cells-09-00749],[@B95-cells-09-00749]\]. They are not only seen in established HCC (47.1%, range 29.3--65.4%). As hepatocellular adenomas transform into HCC, *TERTp* mutations are the first gene recurrently mutated after β-catenin (*CTNNB1*) in preneoplastic cirrhotic lesions \[[@B62-cells-09-00749],[@B95-cells-09-00749]\]. Together with the *CTNNB1* mutation, *TERTp* mutations are considered critical effectors of malignant transformation. As such, they have been proposed as early biomarkers for hepatocellular transformation \[[@B62-cells-09-00749],[@B77-cells-09-00749],[@B95-cells-09-00749],[@B96-cells-09-00749],[@B120-cells-09-00749],[@B121-cells-09-00749]\].

*TERTp* mutations appear to be more frequent in HCV-associated HCC \[[@B62-cells-09-00749],[@B77-cells-09-00749],[@B95-cells-09-00749],[@B96-cells-09-00749],[@B122-cells-09-00749]\] and less frequent or excluded from HBV-associated HCC \[[@B62-cells-09-00749],[@B96-cells-09-00749],[@B121-cells-09-00749],[@B122-cells-09-00749]\], although this remains controversial \[[@B63-cells-09-00749],[@B77-cells-09-00749],[@B95-cells-09-00749]\]. HBV DNA insertion in the *TERTp* is a recurrent mechanism of TERT transcriptional reactivation in HBV-associated HCC \[[@B34-cells-09-00749],[@B123-cells-09-00749],[@B124-cells-09-00749]\], and a genetic screen of *TERT* in HCC found *TERTp* mutations to be mutually exclusive with HBV integration, *TERT* CNVs, and *ATRX* mutations \[[@B121-cells-09-00749]\].

3.6. Cervical and Oral Head and Neck Squamous Cell Carcinoma (HNSCC) {#sec3dot6-cells-09-00749}
--------------------------------------------------------------------

*TERTp* mutations were detected in cervical SCC (20.1%, range 4.5--21.8%) and HNSCC (22.5%, range 17--31.7%) \[[@B36-cells-09-00749],[@B37-cells-09-00749]\]. These malignancies are often associated with high-risk-HPV16/18 E6 and E7 viral oncoproteins and with APOBEC mutations \[[@B125-cells-09-00749],[@B126-cells-09-00749],[@B127-cells-09-00749]\]. High-risk HPV--E6 transactivates *TERT* \[[@B30-cells-09-00749],[@B32-cells-09-00749],[@B33-cells-09-00749],[@B128-cells-09-00749],[@B129-cells-09-00749]\]. *TERTp* mutations have a notably higher prevalence in HPV-negative cervical and oral SCC. This gives distinct patterns of *TERT* reactivation through mutually exclusive mechanisms \[[@B36-cells-09-00749],[@B37-cells-09-00749]\]. In cervical SCC, they are associated with higher TERT levels than HPV16/18-E6-positive tumors and with advanced cervical cancer \[[@B36-cells-09-00749],[@B37-cells-09-00749]\]. Broader studies are needed to evaluate the added value of screening for the molecular mechanism underlying TERT reactivation in cervical and oral SCC.

3.7. The rs2853669 Polymorphism {#sec3dot7-cells-09-00749}
-------------------------------

Among *TERT* polymorphisms, a common polymorphism (rs2853669 A\>G) which disrupts a pre-existing Ets/TCF binding site located 245 bp upstream of the *TERT* TSS has been reported to modify the effect of *TERTp* mutations. It decreases *TERT* transcription in vitro and reverses *TERT* upregulation by *TERTp* mutations \[[@B56-cells-09-00749],[@B61-cells-09-00749],[@B81-cells-09-00749],[@B85-cells-09-00749],[@B130-cells-09-00749]\]. Controversial clinical impacts have been reported, from a beneficial effect on OS and limited tumor recurrence in *TERTp*-mutated urothelial bladder cancer, renal clear cell carcinoma, melanoma, and GBM \[[@B56-cells-09-00749],[@B61-cells-09-00749],[@B81-cells-09-00749],[@B85-cells-09-00749],[@B116-cells-09-00749],[@B131-cells-09-00749]\], to unchanged or worsened clinical outcome in GBM, melanoma, or differentiated thyroid carcinomas \[[@B64-cells-09-00749],[@B65-cells-09-00749],[@B84-cells-09-00749],[@B91-cells-09-00749],[@B102-cells-09-00749],[@B103-cells-09-00749]\]. In HCC, the rs2853669 polymorphism in combination with *TERTp* mutations has been associated with decreased OS and DSF, and increased *TERTp* methylation and expression \[[@B47-cells-09-00749]\]. Possible reasons for these conflicting reports could be homozygosity versus heterozygosity of the variant, or its occurrence on the same allele as *TERTp* mutations. Further studies are needed to assess the relevance of screening for this polymorphism for prognostic and treatment purposes.

4. Cancer Bias of *TERTp* Mutations {#sec4-cells-09-00749}
===================================

*TERTp* mutations have been recorded in individuals of Caucasian, African, and Asian descent, with no race-related bias. The −124 C\>T mutation has an overwhelmingly higher prevalence than the −146 C\>T mutation in all cancers, with the exception of skin cancers, where both hotspots are mutated with comparable frequencies ([Figure 2](#cells-09-00749-f002){ref-type="fig"} and [Table 1](#cells-09-00749-t001){ref-type="table"}). Although both −124C\>T and −146C\>T mutations generate identical sequences, enable binding of GABPA, and are equally efficient in increasing *TERT* transcription in vitro \[[@B57-cells-09-00749],[@B69-cells-09-00749]\], in vivo, the −124 C\>T mutation was associated with higher TERT mRNA in GBM \[[@B57-cells-09-00749],[@B112-cells-09-00749]\]. This would suggest that the Ets/TCF binding site at position −124 provides a more favorable or accessible hotspot for the transcriptional machinery \[[@B109-cells-09-00749]\]. The overrepresentation of the −146 C\>T mutation in skin cancers hints at different etiologies of *TERTp* mutations. *TERTp* mutations in melanoma and non-melanoma skin cancers have been attributed to UV damage \[[@B49-cells-09-00749],[@B51-cells-09-00749],[@B55-cells-09-00749],[@B88-cells-09-00749],[@B89-cells-09-00749],[@B90-cells-09-00749],[@B91-cells-09-00749],[@B116-cells-09-00749]\], which triggers C→T transitions at CC dinucleotides \[[@B55-cells-09-00749],[@B127-cells-09-00749]\]. Nevertheless, C→T transitions where C is preceded by C also conform to the preferred target of Apolipoprotein B mRNA Editing Catalytic Polypeptide-like (APOBEC)3A/B de-aminations and to aging mutations \[[@B127-cells-09-00749],[@B133-cells-09-00749]\]. APOBEC3 mutations are highly prevalent in ovarian and HPV-associated cervical and oral SCC \[[@B125-cells-09-00749],[@B126-cells-09-00749],[@B127-cells-09-00749]\], as well as in HCC and in cirrhotic lesions \[[@B121-cells-09-00749],[@B134-cells-09-00749]\]. A role for APOBEC and aging-associated de-aminations is consistent with potentially increased accessibility of the −124 position to DNA binding proteins and with the association of *TERTp* mutations with older age at diagnosis in GBM, melanoma, and PTC \[[@B52-cells-09-00749],[@B57-cells-09-00749],[@B60-cells-09-00749],[@B63-cells-09-00749],[@B64-cells-09-00749],[@B77-cells-09-00749],[@B79-cells-09-00749],[@B80-cells-09-00749],[@B82-cells-09-00749],[@B86-cells-09-00749],[@B88-cells-09-00749],[@B98-cells-09-00749],[@B100-cells-09-00749],[@B101-cells-09-00749],[@B102-cells-09-00749]\]. These observations therefore raise the possibility that UV-driven lesions account for *TERTp* mutations in skin cancers, while APOBEC and age-driven de-aminations account for the −124 C\>T mutation in other cancers. Further epidemiological and mechanistic studies are needed to shed light on this point.

The −139/−138 CC\>TT tandem mutation is very infrequent, limited to skin cancers, and has been associated with lower DFS. This tandem mutation has been suggested to favor chromosomal instability \[[@B51-cells-09-00749]\].

5. Exclusiveness of *TERTp* Mutations {#sec5-cells-09-00749}
=====================================

Aside from non-melanoma skin cancers \[[@B90-cells-09-00749]\], *TERTp* mutations are mostly monoallelic. This suggests that TERT reactivation on one allele is probably sufficient to ensure telomere maintenance or elongation in cancer cells \[[@B54-cells-09-00749]\]. In line with this observation, *TERTp* mutations appear to be mutually exclusive \[[@B50-cells-09-00749]\]. Likewise, *TERTp* mutations are generally absent from cancers where telomere elongation is ensured by ALT \[[@B77-cells-09-00749],[@B79-cells-09-00749],[@B80-cells-09-00749],[@B98-cells-09-00749]\] or *TERT* copy-number duplications \[[@B38-cells-09-00749],[@B121-cells-09-00749]\]. *TERTp* mutations are also less frequent in cancers where viral transformation or viral oncogenes reactivate *TERT* transcription, such as HBV-DNA or high-risk HPV16/18 E6 \[[@B30-cells-09-00749],[@B32-cells-09-00749],[@B33-cells-09-00749],[@B36-cells-09-00749],[@B37-cells-09-00749],[@B62-cells-09-00749],[@B95-cells-09-00749],[@B96-cells-09-00749],[@B121-cells-09-00749],[@B122-cells-09-00749]\]. These observations reinforce the concept that, despite some exceptions \[[@B38-cells-09-00749],[@B89-cells-09-00749],[@B111-cells-09-00749],[@B117-cells-09-00749]\], tumors generally rely on one mechanism for telomere maintenance. The reasons for such selectivity remain speculative to date. One possible explanation is that there is a threshold for TERT expression, above which the biological advantage is lost.

Consistent with this view, Phosphatidyl Inositol Kinase 3 (PIK3) CA and PIK3 Receptor 1 (PIK3R1) mutations are recorded in 50% of GBM with wt *TERTp* and tend to be mutually exclusive with *TERTp* mutations in ovarian clear cell carcinoma \[[@B79-cells-09-00749],[@B86-cells-09-00749],[@B132-cells-09-00749]\]. The PIK3CA/Akt signaling pathway is involved in cellular self-renewal in embryonic stem cells and cancer stem cells \[[@B135-cells-09-00749]\], as well as in TERT Ser227 and Ser824 phosphorylation, subsequent nuclear translocation, and cellular transformation \[[@B25-cells-09-00749],[@B26-cells-09-00749],[@B27-cells-09-00749],[@B28-cells-09-00749]\]. Mutual exclusion of *PIK3CA* and *TERTp* mutations suggests that activation of the PIK3CA/Akt pathway or of TERT confer cells a similar growth and proliferative advantage. In the absence of TERT reactivation, other telomere maintenance mechanisms, such as ALT, can achieve immortalization \[[@B27-cells-09-00749]\]. Indeed, TERT also contributes to cell survival and proliferation through telomere-independent mechanisms; it facilitates Wnt/β-catenin-dependent \[[@B136-cells-09-00749],[@B137-cells-09-00749]\], c-myc-dependent \[[@B138-cells-09-00749],[@B139-cells-09-00749]\], and NF-κB-dependent gene transcription \[[@B140-cells-09-00749],[@B141-cells-09-00749]\], thereby sustaining both oncogenic signaling pathways and its own transcription in a feedforward loop \[[@B29-cells-09-00749],[@B142-cells-09-00749]\]. It also regulates methylation \[[@B48-cells-09-00749],[@B143-cells-09-00749]\] and DNA damage responses \[[@B144-cells-09-00749],[@B145-cells-09-00749]\], and protects cells from Endoplasmic Reticulum (ER) stress and apoptosis by buffering Reactive Oxygen Species (ROS) and modulating mitochondrial function \[[@B145-cells-09-00749],[@B146-cells-09-00749],[@B147-cells-09-00749],[@B148-cells-09-00749],[@B149-cells-09-00749],[@B150-cells-09-00749],[@B151-cells-09-00749]\]. It is highly likely that TERT homeostasis is also tuned by these functions within a given tumor type and microenvironment, and by related metabolic alterations that need to be preserved.

6. Discussion {#sec6-cells-09-00749}
=============

Hints for a model come from the observation that overall, *TERTp* mutations are associated with late-stage disease in GBM, melanoma, urothelial, and thyroid carcinoma \[[@B49-cells-09-00749],[@B52-cells-09-00749],[@B60-cells-09-00749],[@B61-cells-09-00749],[@B66-cells-09-00749],[@B85-cells-09-00749],[@B98-cells-09-00749],[@B100-cells-09-00749],[@B101-cells-09-00749],[@B103-cells-09-00749],[@B104-cells-09-00749],[@B105-cells-09-00749],[@B112-cells-09-00749],[@B118-cells-09-00749]\] and with the last steps of hepatocellular transformation \[[@B62-cells-09-00749],[@B95-cells-09-00749]\]. They often occur with or after mutations in pathways associated with cell growth and proliferation. In GBM, *TERTp* mutations coexist with *EGFR* amplification \[[@B64-cells-09-00749],[@B77-cells-09-00749],[@B111-cells-09-00749]\], and in urothelial bladder carcinoma, they are associated with *FGFR3* (Fibroblast Growth Factor Receptor 3) mutations \[[@B61-cells-09-00749],[@B94-cells-09-00749]\]. In \~50% of melanoma, urothelial, and thyroid cancers, *TERTp* mutations coexist with the common *BRAF*-V600E mutation \[[@B52-cells-09-00749],[@B88-cells-09-00749],[@B89-cells-09-00749],[@B105-cells-09-00749],[@B106-cells-09-00749],[@B108-cells-09-00749],[@B116-cells-09-00749],[@B152-cells-09-00749]\]. GFR and BRAF/RAS kinases control the MAPK and PI3K-Akt pathways that lead to cell growth, survival, and angiogenesis. Constitutive activation of the GFR/FGFR-BRAF/RAS pathway leads to constitutive cell growth and division \[[@B153-cells-09-00749]\]. Mutations in these oncogenes are often detectable in low-grade tumors and probably precede *TERTp* mutations \[[@B22-cells-09-00749],[@B61-cells-09-00749],[@B77-cells-09-00749],[@B112-cells-09-00749]\]. The picture is even more clear-cut in HCC, where mutations in β-catenin (*CTNNB1*) neatly precede *TERTp* mutations during the process of malignant transformation \[[@B62-cells-09-00749],[@B95-cells-09-00749],[@B120-cells-09-00749]\]. β-catenin is involved in cell adhesion and interacts with Wnt, promoting cell growth and division. The proliferative advantage conferred by driver mutations in these pathways leads to accelerated telomere erosion. Accordingly, most tumors display telomere dysfunction and shortened telomeres, which leads to chromosome instability \[[@B10-cells-09-00749],[@B22-cells-09-00749],[@B61-cells-09-00749],[@B66-cells-09-00749],[@B98-cells-09-00749],[@B112-cells-09-00749],[@B115-cells-09-00749]\]. In this scenario, TERT reactivation regenerates telomeres sufficiently to maintain them above the critical threshold and to stabilize the tumor genome \[[@B3-cells-09-00749],[@B18-cells-09-00749],[@B145-cells-09-00749]\]. This interpretation is consistent with the association of *TERTp* mutations with shortened telomeres and with age as in PTC, melanoma, and GBM/glioma, since cells from younger patients or with sufficiently long telomeres do not need to rely on telomerase reactivation to overcome telomeric crisis \[[@B10-cells-09-00749],[@B29-cells-09-00749],[@B57-cells-09-00749],[@B77-cells-09-00749],[@B85-cells-09-00749],[@B98-cells-09-00749],[@B101-cells-09-00749],[@B115-cells-09-00749]\]. Partial telomere healing is coherent with a modest increase in TERT expression (2- to 4-fold) and with a single genetic mechanism of telomere elongation. It likely reflects an exquisite balance between escape from apoptosis resulting from telomere attrition and genomic instability, and cell sustainability in terms of oxygen and nutrient supplies.

Intriguingly, it was recently reported that GABPA controls the cell cycle and induces cell differentiation, thus acting as a tumor suppressor regulating cell proliferation, stemness, and adhesion. It decreased tumor invasiveness and distal metastases in PTC, HCC, and bladder carcinoma \[[@B154-cells-09-00749],[@B155-cells-09-00749],[@B156-cells-09-00749]\]. GABPA levels were decreased and even negatively associated with TERT expression in PTC \[[@B154-cells-09-00749],[@B155-cells-09-00749],[@B156-cells-09-00749]\]. One possible explanation is that other Ets/TCF family transcription factors bind *TERTp* mutations. Alternatively, the decrease in GABPA expression may follow rather than precede *TERTp* mutations. In this case, it would be a cellular adaptation which confers a selective advantage to *TERTp*-mutated (and *GFR*/*BRAF*/*RAS*-mutated) cells by containing TERT reactivation within sustainable limits. Decreased GABPA could also be an adaptation to the TERT-induced proliferation, stemness, and invasion to avoid contradictory signals. Further studies establishing the order of emergence of these mutations would be needed to shed light on this matter.

Taken together, these observations point to a fine tuning of TERT homeostasis and suggest that there is a narrow kinetic and quantitative window for TERT expression. Below that window, cells succumb to telomere crisis and DNA damage. Above that window, cells succumb to overwhelming genetic alterations or metabolic needs. This frailty could be exploited through strategies aiming to push cells either way beyond the threshold of TERT tolerability.

7. Concluding Remarks {#sec7-cells-09-00749}
=====================

*TERTp* mutations have only been described recently; however, they have prompted an impressive number of studies which draw a comprehensive picture of their prevalence across cancers, as well as providing clues on their mechanisms of action and their associated constraints. They have been proposed as potential biomarkers with predictive and treatment-orienting value. However, more structured studies are needed to validate their clinical potential, particularly since they appear at different stages in different malignancies, ranging from preneoplastic cirrhotic lesions to late stage GBM or melanoma with distal metastases. Cancer cells only require one mechanism of telomere maintenance. This underscores the key role of telomere stabilization in the process of transformation, as well as the necessity of maintaining an exquisitely balanced TERT homeostasis to achieve tumor cell selection, adaptation, and sustainability. TERT is a target of choice in antitumor strategies due to its reactivation in numerous cancers. A better understanding of TERT regulation, homeostasis, and functions could help to overcome the shortcomings of prior genetic and immunotherapy-based approaches targeting TERT.
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###### 

Prevalence and distribution of telomerase reverse transcriptase promoter (*TERTp*) mutations in cancer genomes. The prevalence of *TERTp* mutations is given as percentage and as total number of cases.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cancer Type                                                Stage     Prevalence of Mutations   −146 C\>T   −124 C\>T   Tert Upregulation                             Methods                                            Sample Origin                            Remarks                                                                                                                                                            Ref.
  ---------------------------------------------------------- --------- ------------------------- ----------- ----------- --------------------------------------------- -------------------------------------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------
  Central nervous system (CNS)                                                                                                                                                                                                                                                                                                                                                                                                        

  GBM                                                                  62%\                      25%\        75%\        Yes                                           DNA sequencing,\                                   Patients\                                Associated with older age.                                                                                                                                         \[[@B52-cells-09-00749]\]
                                                                       24/39                     6/24        18/24                                                     qRT-PCR, IHC,                                      (Portugal)                                                                                                                                                                                                  

  GBM                                                        IV        83.9%\                    34%\        65.9%\      Yes                                           DNA sequencing,\                                   Patients\                                Associated with older age.                                                                                                                                         \[[@B57-cells-09-00749]\]
                                                                       47/55                     16/47       31/47                                                     qRT-PCR, TRAP,\                                    (China)                                                                                                                                                                                                     
                                                                                                                                                                       reporter assays                                                                                                                                                                                                                                                

  GBM (Primary)                                              IV        83%\                      24.6%\      75.4%\      N/A                                           DNA sequencing                                     Patients\                                Associated with shorter OS,\                                                                                                                                       \[[@B77-cells-09-00749]\]
                                                                       65/78                     16/65       49/65                                                                                                        (US American)                            *IDH*-wt, *ATRX*-wt, exclusively in *EGFR^mut^* samples.                                                                                                           

  GBM                                                        I--IV     44.6%\                    26.7%\      73.3%\      Yes                                           DNA sequencing,\                                   Patients\                                Associated with late-stage disease and patient age.\                                                                                                               \[[@B60-cells-09-00749]\]
                                                                       45/101                    12/45       33/45                                                     qRT-PCR,\                                          (China)                                  Only in gliomas, not in pituitary adenocarcinomas, meningiomas or secondary metastases.                                                                            
                                                                                                                                                                       reporter assays                                                                                                                                                                                                                                                

  GBM                                                                  55%\                      27%\        73%\        N/A                                           DNA sequencing                                     Patients\                                Associated with shorter OS and with *EGFR^mut^*.\                                                                                                                  \[[@B111-cells-09-00749]\]
                                                                       197/358                   54/197      144/197                                                                                                      (Switzerland)                            Negatively associated with mutant *IDH* and *TP53*.\                                                                                                               
                                                                                                                                                                                                                                                                   More frequent in primary (58%) than in secondary GBM (28%).\                                                                                                       
                                                                                                                                                                                                                                                                   One patient with both −146 C\>T + −124 C\>T mutation.                                                                                                              

  GBM\                                                       IV        80.3%\                    \*          \*          N/A                                           DNA sequencing                                     Patients                                 Associated with shorter OS in patients without rs2853669 *TERT*\                                                                                                   \[[@B81-cells-09-00749]\]
  (primary & secondary)                                                143/178                                                                                                                                                                                     -245 A\>G polymorphism.\                                                                                                                                           
                                                                                                                                                                                                                                                                   Detected in 4/14 (28%) secondary GBM.                                                                                                                              

  GBM                                                        IV        66.9%\                    25.5%\      74.5%\      N/A                                           DNA sequencing                                     Patients (Portugal & Brazil)             Associated with older age, poor prognosis, and shorter survival.\                                                                                                  \[[@B85-cells-09-00749]\]
                                                                       141/211                   36/141      105/141                                                                                                                                               Reversed by rs2853669 *TERT* −245 A\>G polymorphism.                                                                                                               

  GBM                                                                  60.4%\                    24.1%\      75.8%\      Yes                                           DNA sequencing,\                                   Patients (Korea)                         Associated with older age.\                                                                                                                                        \[[@B64-cells-09-00749]\]
                                                                       29/48                     7/29        22/29                                                     qRT-PCR                                                                                     Not associated with OS or DFS.\                                                                                                                                    
                                                                                                                                                                                                                                                                   Associated with *MGMT* methylation and *EGFR* amplification.\                                                                                                      
                                                                                                                                                                                                                                                                   Associated with rs2853669 *TERT* −245 A\>G polymorphism (21/29 patients).\                                                                                         
                                                                                                                                                                                                                                                                   rs2853669 *TERT* −245 A\>G polymorphism reversed TERT upregulation by *TERTp* mutations.                                                                           

  GBM                                                                  73%\                      28%\        82%\        Yes                                           DNA sequencing,\                                                                            Mutually exclusive with *IDH*-1 mutations.\                                                                                                                        \[[@B65-cells-09-00749]\]
                                                                       92/126                    26/92       66/92                                                     qRT-PCR, TRAP,\                                                                             Associated with shorter telomeres.\                                                                                                                                
                                                                                                                                                                       qPCR                                                                                        Associated with lower OS in *IDH*-1wt patients.\                                                                                                                   
                                                                                                                                                                                                                                                                   rs2853669 *TERT* -245 A\>G polymorphism associated with improved OS in patients without *TERTp* mutations, and with worse OS in patients with *TERTp* mutations.   

  GBM (primary)                                                        86%\                      25%\        75%\                                                      DNA sequencing                                                                              Associated with older age and shorter OS.\                                                                                                                         \[[@B84-cells-09-00749]\]
                                                                       79/92                     20/79       69/79                                                                                                                                                 Homozygous rs2853669 *TERT* −245 A\>G polymorphism associated with worse OS in patients without and with *TERTp* mutations.                                        

  GBM and gliomas (primary)                                            100%\                     10%\        90%\        N/A                                           DNA sequencing                                     Patients                                 In primary GBM, characterized by 10q deletion *EFGR* amplification.                                                                                                \[[@B58-cells-09-00749]\]
                                                                       10/10                     1/10        9/10                                                                                                                                                                                                                                                                                                                     

  GBM                                                                  94%\                      36%\        64%\        2.2--286-fold compared to normal astrocytes   DNA sequencing,\                                   Cell lines                                                                                                                                                                                                  \[[@B58-cells-09-00749]\]
                                                                       33/35                     12/33       21/33                                                     qRT-PCR                                                                                                                                                                                                                                                        

  Total GBM                                                            905/1331\                 206/762\    567/762\                                                                                                                                                                                                                                                                                                                 
                                                                       (68%)                     (27%)       (73%)                                                                                                                                                                                                                                                                                                                    

  Oligodendroglioma                                          II        45%\                      20%\        80%\        Yes                                           DNA sequencing,\                                   Patients\                                                                                                                                                                                                   \[[@B52-cells-09-00749]\]
                                                                       10/22                     2/10        8/10                                                      qRT-PCR, IHC                                       (Portugal)                                                                                                                                                                                                  

  Oligodendroglioma                                          II--III   70%\                      14.3%\      85.7%\      Yes                                           DNA sequencing,\                                   Patients\                                Associated with older age.                                                                                                                                         \[[@B57-cells-09-00749]\]
                                                                       7/10                      1/7         6/7                                                       qRT-PCR, TRAP,\                                    (China)                                                                                                                                                                                                     
                                                                                                                                                                       Reporter Assays                                                                                                                                                                                                                                                

  Oligodendroglioma                                          II--III   46.3%\                    24%\        76%\        N/A                                           DNA sequencing                                     Patients\                                Associated with older age at diagnosis.\                                                                                                                           \[[@B85-cells-09-00749]\]
                                                                       25/54                     6/25        19/25                                                                                                        (Portugal &\                             Not associated with lower survival.                                                                                                                                
                                                                                                                                                                                                                          Brazil)                                                                                                                                                                                                     

  Oligodendroglioma                                                    73.5%\                    20%\        80%\        Yes                                           DNA sequencing,\                                   Patients\                                Associated with total 1p19q loss and *IDH-1*/2 mutations (98%) but\                                                                                                \[[@B53-cells-09-00749]\]
                                                                       25/34                     5/25        20/25                                                     qRT-PCR                                            (Japan)                                  exclusive with *IDH*-*1^mut^* if not total loss of 1p19q.                                                                                                          

  Oligodendroglioma                                          II--IV    66.81%\                   \*          \*          N/A                                           DNA sequencing                                     Patients\                                Associated with shorter OS.\                                                                                                                                       \[[@B80-cells-09-00749]\]
                                                                       151/226                                                                                                                                            (US American)                            Can be associated with *ATRX* mutations or *IDH^mut^*/1p19q loss.                                                                                                  

  Oligodendroglioma                                          II--III   63.2%\                    41.7%\      58.3%\      N/A                                           DNA sequencing                                     Patients\                                *IDH*-wt only.\                                                                                                                                                    \[[@B77-cells-09-00749]\]
                                                                       12/19                     5/12        7/12                                                                                                         (US American)                            Associated with worse prognosis in *IDH*-wt.\                                                                                                                      
                                                                                                                                                                                                                                                                   Associated with older age.\                                                                                                                                        
                                                                                                                                                                                                                                                                   Mutually exclusive with *ATRX* mutations.                                                                                                                          

  Anaplastic\                                                III       54%\                      30.8%\      69.2%\      Yes                                           DNA sequencing,\                                   Patients\                                Associated with older age.                                                                                                                                         \[[@B52-cells-09-00749]\]
  oligodendroglioma                                                    13/24                     4/13        9/13                                                      qRT-PCR, IHC,                                      (Portugal)                                                                                                                                                                                                  

  Anaplastic\                                                          74.2%\                    30.4%\      69.6%\      Yes                                           DNA sequencing,\                                   Patients\                                Associated with total 1p19q loss and *IDH*-1/2 mutations (98%) but\                                                                                                \[[@B53-cells-09-00749]\]
  oligodendroglioma                                                    23/31                     7/23        16/23                                                     qRT-PCR                                            (Japan)                                  exclusive with *IDH*-1 if not total loss of 1p19q.                                                                                                                 

  Anaplastic\                                                III       88.5%\                    43.5%\      56.5%\      N/A                                           DNA sequencing                                     Patients\                                Associated with older age.\                                                                                                                                        \[[@B77-cells-09-00749]\]
  oligodendroglioma                                                    23/26                     10/23       13/23                                                                                                        (US American)                            *IDH*-wt only.\                                                                                                                                                    
                                                                                                                                                                                                                                                                   Associated with worse prognosis in *IDH*-wt.\                                                                                                                      
                                                                                                                                                                                                                                                                   Mutually exclusive with *ATRX* mutations.                                                                                                                          

  Total\                                                               289/446\                  40/138\     98/138\                                                                                                                                                                                                                                                                                                                  
  Oligodendroglioma                                                    (64.7%)                   (29%)       (71%)                                                                                                                                                                                                                                                                                                                    

  Diffuse astrocytomas                                                 19.2%\                    20%\        80%\        Yes                                           DNA sequencing,\                                   Patients\                                Associated with total 1p19q loss and *IDH*-1/2 mutations (98%) but\                                                                                                \[[@B53-cells-09-00749]\]
                                                                       10/52                     2/10        8/10                                                      qRT-PCR                                            (Japan)                                  exclusive with *IDH*-1 if not total loss of 1p19q.                                                                                                                 

  Diffuse astrocytoma                                        II        15%\                      33,3%\      66,6%\      Yes                                           DNA sequencing,\                                   Patients\                                Associated with older age.                                                                                                                                         \[[@B52-cells-09-00749]\]
                                                                       3/20                      1/3         2/3                                                       qRT-PCR, IHC                                       (Portugal)                                                                                                                                                                                                  

  Diffuse astrocytoma                                        II        20%\                      25%\        62.5%\      Yes                                           DNA sequencing,\                                   Patients\                                Associated with age.                                                                                                                                               \[[@B57-cells-09-00749]\]
                                                                       8/40                      2/8         5/8                                                       qRT-PCR, TRAP,\                                    (China)                                                                                                                                                                                                     
                                                                                                                                                                       reporter assays                                                                                                                                                                                                                                                

  Diffuse astrocytoma                                        II        15.2%\                    16.7%\      83.3%\      N/A                                           DNA sequencing                                     Patients\                                Frequency increased with grade.                                                                                                                                    \[[@B85-cells-09-00749]\]
                                                                       7/46                      1/7         6/7                                                                                                          (Portugal &\                                                                                                                                                                                                
                                                                                                                                                                                                                          Brazil)                                                                                                                                                                                                     

  Total Diffuse Astrocytoma                                            28/158\                   6/28\       21/28\                                                                                                                                                                                                                                                                                                                   
                                                                       (17.7%)                   (21.4%)     (75%)                                                                                                                                                                                                                                                                                                                    

  Astocytoma                                                 II--IV    62.5%\                    N/A         N/A         N/A                                           DNA sequencing                                     Patients\                                Associated with shorter OS.\                                                                                                                                       \[[@B80-cells-09-00749]\]
                                                                       416/665                                                                                                                                            (US American)                            Can be associated with *ATRX* mutations or IDHmut/1p1q loss.                                                                                                       

  Anaplastic Astrocytomas                                    III       10%\                      0%\         100%\       N/A                                           DNA sequencing                                     Patients\                                Frequency increased with grade.                                                                                                                                    \[[@B85-cells-09-00749]\]
                                                                       1/10                      0/1         1/1                                                                                                          (Portugal &\                                                                                                                                                                                                
                                                                                                                                                                                                                          Brazil)                                                                                                                                                                                                     

  Anaplastic Astrocytoma                                     III       33.3%\                    0%\         100%\       Yes                                           DNA sequencing,\                                   Patients\                                Correlation with age.                                                                                                                                              \[[@B57-cells-09-00749]\]
                                                                       4/12                      0/4         4/4                                                       qRT-PCR, TRAP,\                                    (China)                                                                                                                                                                                                     
                                                                                                                                                                       reporter assays                                                                                                                                                                                                                                                

  Anaplastic Astrocytomas                                    III       25.3%\                    20%\        80%\        Yes                                           DNA sequencing,\                                   Patients\                                Associated with total 1p19q loss and *IDH*-1/2 mutations (98%) but exclusive with *IDH*-1 if not total loss of 1p19q.                                              \[[@B53-cells-09-00749]\]
                                                                       20/79                     4/20        16/20                                                     qRT-PCR                                            (Japan)                                                                                                                                                                                                     

  Total Anaplastic Astrocytomas                                        25/101\                   4/25\       21/25\                                                                                                                                                                                                                                                                                                                   
                                                                       (24.7%)                   (16%)       (84%)                                                                                                                                                                                                                                                                                                                    

  Mixed Oligoastocytoma                                      II--IV    32.3%\                    \*          \*          N/A                                           DNA sequencing                                     Patients\                                Associated with shorter OS.\                                                                                                                                       \[[@B80-cells-09-00749]\]
                                                                       63/195                                                                                                                                             (US\                                     Can be associated with *ATRX* mutations or *IDH^mut^*/1p1q loss.                                                                                                   
                                                                                                                                                                                                                          American)                                                                                                                                                                                                   

  Oligoastrocytoma                                                     40%\                      28.6%\      71.4%\      Yes                                           DNA sequencing,\                                   Patients\                                Associated with total 1p19q loss and *IDH*-1/2 mutations (98%) but exclusive with *IDH*-1 if not total loss of 1p19q.                                              \[[@B53-cells-09-00749]\]
                                                                       14/35                     4/14        10/14                                                     qRT-PCR                                            (Japan)                                                                                                                                                                                                     

  Oligoastrocytoma                                           II--III   40.0%\                    50%\        50%\        N/A                                           DNA sequencing                                     Patients\                                Not associated with lower survival.                                                                                                                                \[[@B85-cells-09-00749]\]
                                                                       4/10                      2/4         2/4                                                                                                          (Portugal & Brazil)                                                                                                                                                                                         

  Anaplastic Oligoastrocytoma                                          48.9%\                    27.3%\      72.7%\      Yes                                           DNA sequencing,\                                   Patients (Japan)                         Associated with total 1p19q loss and *IDH*-1/2 mutations (98%) but exclusive with *IDH*-1 if not total loss of 1p19q.                                              \[[@B53-cells-09-00749]\]
                                                                       22/45                     6/22        16/22                                                     qRT-PCR                                                                                                                                                                                                                                                        

  Total\                                                               103/285\                  12/40\      28/40\                                                                                                                                                                                                                                                                                                                   
  Oligoastrocytoma                                                     (36.1%)                   (30%)       (70%)                                                                                                                                                                                                                                                                                                                    

  Medulloblastoma                                                      33.3%\                    50%\        50%\        N/A                                           DNA sequencing                                     Patients (China)                         Associated with age.                                                                                                                                               \[[@B57-cells-09-00749]\]
                                                                       2/6                       1/2         1/2                                                                                                                                                                                                                                                                                                                      

  Medulloblastoma                                                      20.9%\                    0%0/19      100%\       N/A                                           DNA sequencing                                     Patients\                                *IDH*-wt and *ATRX*-wt only.\                                                                                                                                      \[[@B77-cells-09-00749]\]
                                                                       19/91                                 19/19                                                                                                        (US American)                            Associated with worse prognosis in *IDH*-1-wt.\                                                                                                                    
                                                                                                                                                                                                                                                                   Associated with older age.\                                                                                                                                        
                                                                                                                                                                                                                                                                   Mutually exclusive with ALT.                                                                                                                                       

  Total\                                                               21/97\                    1/21\       20/21\                                                                                                                                                                                                                                                                                                                   
  Medulloblastoma                                                      (21.6%)                   (4.7%)      (95.3%)                                                                                                                                                                                                                                                                                                                  

  Skin                                                                                                                                                                                                                                                                                                                                                                                                                                

  Melanoma                                                             71%\                      46%\        54%\        Yes                                           DNA sequencing,\                                   Patients\                                                                                                                                                                                                   \[[@B50-cells-09-00749]\]
                                                                       50/70                     23/50       27/50                                                     reporter vectors                                   & cell lines                                                                                                                                                                                                

  Melanoma                                                             32.5%\                    20%\        28%\        N/A                                           DNA sequencing                                     Patients                                 -57 C\>T germline mutation in family with history of melanoma.\                                                                                                    \[[@B49-cells-09-00749]\]
                                                                       25/77                     5/25        7/25                                                                                                                                                  High prevalence in metastatic cell lines (85%) compared to primary melanoma (32.5%).\                                                                              
                                                                                                                                                                                                                                                                   CC\>TT −139/−138 tandem mutation in 10.4% patients.\                                                                                                               
                                                                                                                                                                                                                                                                   Concomitant with *BRAF* mutations in 47% of cases.                                                                                                                 

  Melanoma                                                             29%\                      50%\        50%\        N/A                                           DNA sequencing                                     Patients\                                Associated with *BRAF* mutations.                                                                                                                                  \[[@B52-cells-09-00749]\]
                                                                       16/56                     8/16        8/16                                                                                                         (Portugal)                                                                                                                                                                                                  

  Melanoma                                                             34%\                      52.5%\      36%\        Yes                                           DNA sequencing,\                                   Patients\                                CC\>TT −139/−138 tandem mutations in 4/97 (4.1%) patients.\                                                                                                        \[[@B88-cells-09-00749]\]
                                                                       97/287                    51/97       35/97                                                     qRT-PCR                                            (Spain)                                  Associated with *BRAF* mutations in 50% cases.                                                                                                                     

  Melanoma                                                             41.6%\                    \*          \*          N/A                                           DNA sequencing                                     Patients (Spain)                         Associated with shorter telomeres in tumor and with accelerated telomere shortening rate.\                                                                         \[[@B115-cells-09-00749]\]
                                                                       121/291                                                                                                                                                                                     Associated with *BRAF*/*NRAS* mutation in 75/243 cases.\                                                                                                           
                                                                                                                                                                                                                                                                   Telomere shortening rate: *BRAF*/NRAS^mut^+*TERTp^mut^*\>*TERTp^mut^*\>*BRAF*/*NRAS^mut^*                                                                          

  Melanoma                                                             22%\                      35%\        46%\        Yes                                           DNA sequencing,\                                   Patients\                                Associated with reduced OS & DFS.\                                                                                                                                 \[[@B89-cells-09-00749]\]
                                                                       26/116                    9/26        12/26                                                     IHC                                                (Portugal)                               More prevalent in sun-exposed regions.\                                                                                                                            
                                                                                                                                                                                                                                                                   Associated with increased mitotic rates.\                                                                                                                          
                                                                                                                                                                                                                                                                   −138/−138 CC\>TT tandem mutation in 2/26 (7.7%) patients.\                                                                                                         
                                                                                                                                                                                                                                                                   −125/−124 CC\>TT tandem mutation in 3/26 (11.5%) patients.\                                                                                                        
                                                                                                                                                                                                                                                                   Associated with *BRAF*-V600E mutation (58% of cases).                                                                                                              

  Melanoma                                                             38.6%\                    50%\        32.8%\      N/A                                           DNA sequencing                                     Patients (Spain)                         Associated with shorter OS and DFS.\                                                                                                                               \[[@B116-cells-09-00749]\]
                                                                       116/300                   58/116      32/116                                                                                                                                                −139/−138 CC\>TT & −125/−124 CC\>TT tandem mutations in 16/116 cases (13.8%).\                                                                                     
                                                                                                                                                                                                                                                                   Associated with *BRAF*/*NRAS* mutations in 126/283 (44.5%) cases.\                                                                                                 
                                                                                                                                                                                                                                                                   Reversed by rs2853669 *TERT* -245 A\>G polymorphism.                                                                                                               

  Melanoma                                                             54.8%\                    61.9%\      30.2%\      N/A                                           DNA sequencing                                     Patients (Austria)                       −139/−138 CC\>TT tandem mutations in 4/63 (6.3%) patients.\                                                                                                        \[[@B91-cells-09-00749]\]
                                                                       63/115                    39/63       19/63                                                                                                                                                 −125/−124 CC\>TT tandem mutation in 1/63 (1.6%) patient.\                                                                                                          
                                                                                                                                                                                                                                                                   Associated with *BRAF*/*NRAS* mutation in 75/243 cases.\                                                                                                           
                                                                                                                                                                                                                                                                   Associated with rs2853669 *TERT* -245 A\>G polymorphism.                                                                                                           

  Total Melanoma                                                       514/1312\                 193/398\    140/398\                                                                                                                                                                                                                                                                                                                 
                                                                       (39.2%)                   (48.5%)     (35.1%)                                                                                                                                                                                                                                                                                                                  

  Basal cell carcinoma                                                 55.6%\                    55.6%\      22.2%\      N/A                                           DNA sequencing                                     Patients (Germany)                                                                                                                                                                                          \[[@B55-cells-09-00749]\]
                                                                       18/32                     10/18       4/18                                                                                                                                                                                                                                                                                                                     

  Basal cell carcinoma\                                                74%\                      35.5%\      45.1%\      N/A                                           DNA sequencing                                     Patients                                 Mostly homozygous.\                                                                                                                                                \[[@B90-cells-09-00749]\]
  (sporadic & nevoid)                                                  31/42                     11/31       14/31                                                                                                                                                 −139/−138 CC\>TT tandem mutation in 7/31 (22.6%) patients.\                                                                                                        
                                                                                                                                                                                                                                                                   −125/−124 CC--TT tandem mutation in 5/31 (16.1%) patients.\                                                                                                        
                                                                                                                                                                                                                                                                   1 patient with −139/−138 CC\>TT + −125/−124 CC\>TT tandem mutations.\                                                                                              
                                                                                                                                                                                                                                                                   Mutations more frequent in basal cell carcinoma than in squamous cell carcinoma.                                                                                   

  Basal cell carcinoma                                                 38.7%\                    43%\        49%\        no                                            DNA sequencing,\                                   Patients\                                No correlation with clinical parameters.\                                                                                                                          \[[@B89-cells-09-00749]\]
                                                                       76/196                    33/76       37/76                                                     IHC                                                (Portugal)                               Higher prevalence in patients not exposed to X-irradiation: 48/94 (51%) vs. 28/102 (27%) in X-irradiated patients.\                                                
                                                                                                                                                                                                                                                                   −124 C\>T more frequent than −146 C\>T in non-X-irradiated patients;\                                                                                              
                                                                                                                                                                                                                                                                   −146 C\>T more frequent in X-irradiated patients.\                                                                                                                 
                                                                                                                                                                                                                                                                   −139/138 CC\>TT tandem mutation in 2/76 (2.6%) patients,\                                                                                                          
                                                                                                                                                                                                                                                                   2 patients with −146 C\>T + −124 C\>T mutations.                                                                                                                   

  Total Basal cell carcinoma                                           125/270\                  54/125\     55/125\                                                                                                                                                                                                                                                                                                                  
                                                                       (46.2%)                   (43.2%)     (44%)                                                                                                                                                                                                                                                                                                                    

  Cutaneous SCC                                                        50%\                      29.4%\      29.4%\      N/A                                           DNA sequencing                                     Patients (Germany)                                                                                                                                                                                          \[[@B55-cells-09-00749]\]
                                                                       17/34                     5/17        5/17                                                                                                                                                                                                                                                                                                                     

  Cutaneous SCC                                                        50%\                      54%\        31%\        N/A                                           DNA sequencing                                     Patients                                 Mostly homozygous.\                                                                                                                                                \[[@B90-cells-09-00749]\]
                                                                       13/26                     7/13        4/13                                                                                                                                                  −139/−138 CC\>TT tandem mutation in 2/13 (15.4) patients.\                                                                                                         
                                                                                                                                                                                                                                                                   Mutations more frequent in basal cell carcinoma than in squamous cell carcinoma.                                                                                   

  Total Cutaneous SCC                                                  30/60\                    12/30\      9/30\                                                                                                                                                                                                                                                                                                                    
                                                                       (50%)                     (40%)       (30%)                                                                                                                                                                                                                                                                                                                    

  Bladder/urinary tract cancers                                                                                                                                                                                                                                                                                                                                                                                                       

  Bladder Cancer                                                       85%\                      4.5%\       95.5%\      N/A                                           DNA sequencing                                     Patients (China)                                                                                                                                                                                            \[[@B78-cells-09-00749]\]
                                                                       44/52                     2/44        42/44                                                                                                                                                                                                                                                                                                                    

  Urothelial bladder carcinoma                               III       80%\                      17%\        83%\        N/A                                           DNA sequencing                                     Patients\                                                                                                                                                                                                   \[[@B93-cells-09-00749]\]
                                                                       12/15                     2/12        10/12                                                                                                        (US American)                                                                                                                                                                                               

  Urothelial bladder carcinoma                                         66.7%\                    28.6%\      71.4%\      N/A                                           DNA sequencing                                     Patients\                                                                                                                                                                                                   \[[@B77-cells-09-00749]\]
                                                                       14/21                     4/14        10/14                                                                                                        (US American)                                                                                                                                                                                               

  Urothelial bladder carcinoma                                         61.7%\                    25%\        58.8%\      N/A                                           DNA sequencing                                     Patients (China)                         Not associated with age.                                                                                                                                           \[[@B57-cells-09-00749]\]
                                                                       148/240                   37/148      87/148                                                                                                                                                                                                                                                                                                                   

  Urothelial bladder carcinoma                                         59%\                      37.5%\      62.5%\      N/A                                           DNA sequencing, qRT-PCR                            Patients (Portugal)                      Not associated with age.\                                                                                                                                          \[[@B52-cells-09-00749]\]
                                                                       48/82                     18/48       30/48                                                                                                                                                 Low-grade bladder cancer: 67%,\                                                                                                                                    
                                                                                                                                                                                                                                                                   high-grade bladder cancer: 56%.                                                                                                                                    

  Urothelial bladder carcinoma                                         65.4%\                    17.8%\      81.8%\      N/A                                           DNA sequencing, relative telomere length           Patients (Sweden)                        Associated with shorter telomeres and worse OS.\                                                                                                                   \[[@B61-cells-09-00749]\]
                                                                       214/327                   38/214      175/214                                                                                                                                               Associated with *FGFR3* mutation in 45% of tumors.\                                                                                                                
                                                                                                                                                                                                                                                                   *FGFR3* mutations found in low-grade tumors, *TERTp* mutations in low-grade and high-grade tumors.\                                                                
                                                                                                                                                                                                                                                                   Reversed by rs2853669 *TERT* −245 A\>G polymorphism.                                                                                                               

  Urothelial bladder carcinoma                                         77.1%\                    17%\        83%\        Not increased                                 DNA sequencing, qRT-PCR                            Patients                                 Not associated with OS, DFS, or clinical outcome.\                                                                                                                 \[[@B94-cells-09-00749]\]
                                                                       361/468                   62/361      299/361                                                                                                                                               Associated with *FGFR3^mut^*.                                                                                                                                      

  Urothelial bladder carcinoma                                         100%\                     12%\        85%\        N/A                                           DNA sequencing                                     Patients                                 Pure micropapillary carcinoma and urothelial cancer with focal micropapillary features.                                                                            \[[@B92-cells-09-00749]\]
                                                                       33/33                     5/33        28/33                                                                                                                                                                                                                                                                                                                    

  Urothelial upper tract urinary carcinoma                             76.9%\                    12.5%\      72.5%\      N/A                                           DNA sequencing                                     Patients\                                Not associated with age.                                                                                                                                           \[[@B57-cells-09-00749]\]
                                                                       40/52                     5/40        29/40                                                                                                        (China)                                                                                                                                                                                                     

  Urothelial upper tract urinary carcinoma                             47.4%\                    11.1%\      88.9%\      N/A                                           DNA sequencing                                     Patients\                                                                                                                                                                                                   \[[@B77-cells-09-00749]\]
                                                                       9/19                      1/9         8/9                                                                                                          (US American)                                                                                                                                                                                               

  Urothelial upper tract urinary carcinoma                             29.5%\                    18.5%\      81.5%\      N/A                                           DNA sequencing,\                                   Patients (China)                         Associated with distant metastases.                                                                                                                                \[[@B118-cells-09-00749]\]
                                                                       65/220                    12/65       53/65                                                     Detection in urine                                                                                                                                                                                                                                             

  Total Urothelial bladder & upper tract urinary carcinoma             988/1529\                 186/988\    771/988\                                                                                                                                                                                                                                                                                                                 
                                                                       (64.6%)                   (18.8%)     (78%)                                                                                                                                                                                                                                                                                                                    

  Thyroid                                                                                                                                                                                                                                                                                                                                                                                                                             

  Differentiated thyroid cancer                                        12.2%\                    4.9%\       95.1%\      N/A                                           DNA sequencing                                     Patients                                 Only in malignant lesions.                                                                                                                                         \[[@B108-cells-09-00749]\]
                                                                       41/336                    2/41        39/41                                                                                                                                                                                                                                                                                                                    

  Papillary thyroid cancer                                             8%\                       7.7%\       84.6%\      Yes                                           DNA sequencing,\                                   Patients\                                                                                                                                                                                                   \[[@B52-cells-09-00749]\]
                                                                       13/169                    1/13        11/13                                                     qRT-PCR, IHC                                       (Portugal)                                                                                                                                                                                                  

  Papillary thyroid cancer                                   III/IV    11.3%\                    15.2%\      85.8%\      N/A                                           DNA sequencing                                     Patients (China)                         Associated with older age, larger tumor size, extrathyroid invasion, advanced clinical stage.\                                                                     \[[@B99-cells-09-00749]\]
                                                                       46/408                    7/46        39/46                                                                                                                                                 Associated with *BRAF*-V600E mutation.                                                                                                                             

  Papillary thyroid cancer                                             27%\                      7.7%\       92.3%\      N/A                                           DNA sequencing                                     Patients (Sweden)                        Only in patients \>45.\                                                                                                                                            \[[@B98-cells-09-00749]\]
                                                                       13/51                     1/13        12/13                                                                                                                                                 Correlated with shorter telomeres and distal metastases.\                                                                                                          
                                                                                                                                                                                                                                                                   PTC: 27% (25/332); FTC: 22% (12/70); ATC: 50% (12/36).                                                                                                             

  Papillary thyroid cancer                                   III/IV    4.1%\                     \*          \*          N/A                                           DNA sequencing                                     Patients (Korea)                         Associated with *BRAF*/*RAS* mutations.\                                                                                                                           \[[@B106-cells-09-00749]\]
                                                                       18/432                                                                                                                                                                                      Associated with tumor size, stage III-IV, recurrence, decreased OS and DFS with BRAF/RAS mutations: *RAS*/*BRAF* \>*TERTp* \> R*A*S/*BRAF*+*TERTp*.                

  Papillary thyroid cancer                                             11.7%\                    0%\         100%\       N/A                                           DNA sequencing                                     Patients                                 Only in malignant lesions.\                                                                                                                                        \[[@B108-cells-09-00749]\]
                                                                       30/257                    0/30        30/30                                                                                                                                                 −124 C\>T associated with *BRAF*-V600E mutation.                                                                                                                   

  Papillary thyroid cancer                                             37.7%\                    10%\        90%\        N/A                                           DNA sequencing                                     Patients (Korea)                         No *TERTp* mutation found in 192 well differentiated cancers without distant metastasis.                                                                           \[[@B105-cells-09-00749]\]
                                                                       10/27                     1/10        9/10                                                                                                                                                                                                                                                                                                                     

  Papillary thyroid cancer                                             22%\                      44%\        66%\        N/A                                           DNA sequencing                                     Patients\                                More frequent in *BRAF*-wt patients than in *BRAF^mut^*.                                                                                                           \[[@B100-cells-09-00749]\]
                                                                       18/80                     8/18        10/18                                                                                                        (US & Japan)                                                                                                                                                                                                

  Papillary thyroid cancer                                             31.8%\                    0%\         100%\       N/A                                           DNA sequencing                                     Patients\                                Associated with older age (\>45 years), larger tumor size, stage III--IV, distant metastases, decreased OS and DFS.\                                               \[[@B103-cells-09-00749]\]
                                                                       77/242                    0/77        77/77                                                                                                        (US)                                     rs2853669 *TERT* −245 A\>G polymorphism (46.7% (113/242)of patients) increases OS & DFS in patients without *TERTp* mutations and with *BRAF*-V600E.               

  Papillary thyroid cancer                                             12%\                      14.6%\      86.4%\      Yes                                           DNA sequencing,\                                   Patients\                                Associated with older age and poor prognosis.\                                                                                                                     \[[@B102-cells-09-00749]\]
                                                                       22/182                    3/22        19/22                                                     WB, and IHC                                        (Italy)                                  Increased cytoplasmic localization of TERT.\                                                                                                                       
                                                                                                                                                                                                                                                                   No impact of rs2853669 *TERT* -245 A\>G polymorphism on outcome.                                                                                                   

  Total Papillary thyroid cancer                                       247/1848\                 21/229\     207/229\                                                                                                                                                                                                                                                                                                                 
                                                                       (13.4%)                   (9.2%)      (90.4%)                                                                                                                                                                                                                                                                                                                  

  Follicular Thyroid Cancer                                            13.9%\                    18.2%\      81.8%\      N/A                                           DNA sequencing                                     Patients                                 Only in malignant lesions.                                                                                                                                         \[[@B108-cells-09-00749]\]
                                                                       11/79                     2/11        9/11                                                                                                                                                                                                                                                                                                                     

  Follicular Thyroid Cancer                                            66.7%\                    50%\        50%\        N/A                                           DNA sequencing                                     Patients (Korea)                         No *TERTp* mutation found in 192 well-differentiated cancers without distanst metastasis.                                                                          \[[@B105-cells-09-00749]\]
                                                                       2/3                       1/2         1/2                                                                                                                                                                                                                                                                                                                      

  Follicular thyroid Cancer                                            14%\                      22.2%\      77.8%\      Yes                                           DNA sequencing,\                                   Patients (Portugal)                                                                                                                                                                                         \[[@B52-cells-09-00749]\]
                                                                       9/64                      2/9         7/9                                                       qRT-PCR, IHC                                                                                                                                                                                                                                                   

  Follicular thyroid cancer                                            22%\                      12.5%\      87.5%\      N/A                                           DNA sequencing                                     Patients (Sweden)                        Increased prevalence in ATC: PTC: 27% (25/332); FTC: 22% (12/70); ATC: 50% (12/36).                                                                                \[[@B98-cells-09-00749]\]
                                                                       8/36                      1/8         7/8                                                                                                                                                                                                                                                                                                                      

  Follicular thyroid cancer                                            36.4%\                    12.5%\      87.5%\      N/A                                           DNA sequencing                                     Patients (China)                         Associated with older age, larger tumor size, extrathyroid invasion, advanced clinical stage.\                                                                     \[[@B99-cells-09-00749]\]
                                                                       8/22                      1/8         7/8                                                                                                                                                   Associated with *BRAF*-V600E mutation.                                                                                                                             

  Follicular thyroid cancer                                  III/IV    5.9%\                     \*          \*          N/A                                           DNA sequencing                                     Patients (Korea)                         Associated with *BRAF*/*RAS* mutations.\                                                                                                                           \[[@B106-cells-09-00749]\]
                                                                       7/119                                                                                                                                                                                       Associated with tumor size, stage III-IV, recurrence, decreased OS and DFS with *BRAF*/*RAS* mutations: *RAS*/*BRAF* \>*TERTp* \> *RAS*/*BRAF*+*TERTp*.            

  Follicular thyroid cancer                                            14%\                      38.5%\      62.5%\      Yes                                           DNA sequencing,\                                   Patients (Italy)                         Associated with older age and poor prognosis.\                                                                                                                     \[[@B102-cells-09-00749]\]
                                                                       8/58                      3/8         5/8                                                       WB, and IHC                                                                                 Increased cytoplasmic TERT.\                                                                                                                                       
                                                                                                                                                                                                                                                                   No impact of rs2853669 *TERT* -245 A\>G polymorphism on outcome.                                                                                                   

  Total Follicular thyroid cancer                                      53/381\                   10/46\      36/46\                                                                                                                                                                                                                                                                                                                   
                                                                       (13.9%)                   (21.7%)     (78.2%)                                                                                                                                                                                                                                                                                                                  

  Poorly differentiated thyroid cancer                                 21%\                      33.3\       66.7\       Yes                                           DNA sequencing,\                                   Patients (Portugal)                                                                                                                                                                                         \[[@B52-cells-09-00749]\]
                                                                       3/14                      1/3         2/3                                                       qRT-PCR, IHC                                                                                                                                                                                                                                                   

  Poorly differentiated thyroid cancer                                 37.5%\                    0%\         100%\       N/A                                           DNA sequencing                                     Patients                                 Only in malignant lesions.                                                                                                                                         \[[@B108-cells-09-00749]\]
                                                                       3/8                       0/3         3/3                                                                                                                                                                                                                                                                                                                      

  Poorly differentiated thyroid cancer                                 29%\                      50%\        50%\        N/A                                           DNA sequencing                                     Patients (Korea)                         No *TERTp* mutation found in 192 well-differentiated cancers without distanst metastasis.                                                                          \[[@B105-cells-09-00749]\]
                                                                       2/7                       1/2         1/2                                                                                                                                                                                                                                                                                                                      

  Poorly differentiated thyroid cancer                                 51.7%\                    40%\        60%\        N/A                                           DNA sequencing                                     Patients\                                More prevalent in advanced cancer patients with *BRAF*/*RAS^mut^*.                                                                                                 \[[@B100-cells-09-00749]\]
                                                                       30/58                     12/30       18/30                                                                                                        (US & Japan)                                                                                                                                                                                                

  Total Poorly differentiated thyroid cancer                           38/87\                    14/38\      24/38\                                                                                                                                                                                                                                                                                                                   
                                                                       (43.7%)                   (36.8%)     (63.2%)                                                                                                                                                                                                                                                                                                                  

  Anaplastic thyroid cancer                                            46.3%\                    8%\         92%\        N/A                                           DNA sequencing                                     Patients                                 Only in malignant lesions.                                                                                                                                         \[[@B108-cells-09-00749]\]
                                                                       25/54                     2/25        23/25                                                                                                                                                                                                                                                                                                                    

  Anaplastic thyroid cancer                                            13%\                      50%\        50%\        Yes                                           DNA sequencing, qRT-PCR                            Patients (Portugal)                                                                                                                                                                                         \[[@B52-cells-09-00749]\]
                                                                       2/16                      1/2         1/2                                                                                                                                                                                                                                                                                                                      

  Anaplastic thyroid cancer                                            50%\                      0%\         100%\       N/A                                           DNA sequencing                                     Patients\                                More prevalent in advanced cancer patients with *BRAF*/*RAS^mut^*.                                                                                                 \[[@B100-cells-09-00749]\]
                                                                       10/20                     0/10        10/10                                                                                                        (US & Japan)                                                                                                                                                                                                

  Anaplastic thyroid cancer                                            50%\                      20%\        80%\        N/A                                           DNA sequencing                                     Patients (Sweden)                        PTC: 27% (25/332); FTC: 22% (12/70); ATC: 50% (12/36).                                                                                                             \[[@B98-cells-09-00749]\]
                                                                       10/20                     2/10        8/10                                                                                                                                                                                                                                                                                                                     

  Anaplastic thyorid cancer                                            33.3%\                    \*          \*          N/A                                           DNA sequencing                                     Patients\                                Associated with older age, larger tumor size, distant metastases and disease-related death in FTC.\                                                                \[[@B101-cells-09-00749]\]
                                                                       12/36                                                                                                                                              (Portugal & Spain)                       PTC: 7.5% (25/332); FTC: 17.1% (12/70); PDTC: 29% (9/31); ATC: 33.4% (12/36).\                                                                                     
                                                                                                                                                                                                                                                                   PTC associated with *BRAF*-V600E mutation in 60.3% of cases.                                                                                                       

  Anaplastic thyroid cancer                                            38.7%\                    10%\        90%\        N/A                                           DNA sequencing                                     Patients\                                Associated with older age and distal metastases.\                                                                                                                  \[[@B104-cells-09-00749]\]
                                                                       41/106                    4/41        37/41                                                                                                        (US & China)                             −124 C\>T found in 56.3% of *BRAF*-V600E mutated cases.                                                                                                            

  Total anaplastic thyroid cancer                                      100/252\                  9/88\       79/88\                                                                                                                                                                                                                                                                                                                   
                                                                       (39.7%)                   (10.2%)     (89.7%)                                                                                                                                                                                                                                                                                                                  

  Thyroid Cancer cell lines                                            91.7%\                    27.3%\      72.7%\      N/A                                           DNA sequencing                                     Cell lines                                                                                                                                                                                                  \[[@B108-cells-09-00749]\]
                                                                       11/12                     3/11        8/11                                                                                                                                                                                                                                                                                                                     

  Thyroid Cancer cell lines                                            75%\                      17.7%\      83.3%\      N/A                                           DNA sequencing                                     ATC cell lines                                                                                                                                                                                              \[[@B98-cells-09-00749]\]
                                                                       6/8                       1/6         5/6                                                                                                                                                                                                                                                                                                                      

  Liver-Hepatocellular Carcinoma (HCC)                                                                                                                                                                                                                                                                                                                                                                                                

  HCC                                                                  31.4%\                    18,2%\      81,8%\      N/A                                           DNA sequencing                                     Patients (China)                                                                                                                                                                                            \[[@B57-cells-09-00749]\]
                                                                       11/35                     2/11        9/11                                                                                                                                                                                                                                                                                                                     

  HCC                                                                  34%\                      33.3%\      66.7%\      N/A                                           DNA sequencing                                     Patients\                                Higher *TERTp* mutation prevalence in African (53%) compared to non-African (24%) populations.                                                                     \[[@B97-cells-09-00749]\]
                                                                       15/44                     5/15        10/15                                                                                                        (Africa, Asia, Europe)                                                                                                                                                                                      

  HCC                                                                  44.3%\                    3.7%\       96.3%\      N/A                                           DNA sequencing                                     Patients\                                Detected in both HBV-associated and HBV-independent HCC\                                                                                                           \[[@B77-cells-09-00749]\]
                                                                       27/61                     1/27        26/27                                                                                                        (US American)                            Frequent in HCV-associated HCC.                                                                                                                                    

  HCC                                                                  48.5%\                    3.1%\       96.9%\      N/A                                           DNA sequencing                                     Patients (Italy)                         41% of mutations in HBV-associated HCC.\                                                                                                                           \[[@B95-cells-09-00749]\]
                                                                       65/131                    2/65        63/65                                                                                                                                                 53.6% mutations in HCV-associated HCC.\                                                                                                                            
                                                                                                                                                                                                                                                                   All heterozygous.\                                                                                                                                                 
                                                                                                                                                                                                                                                                   No −57 A\>C.                                                                                                                                                       

  HCC                                                                  31%\                      1.1%\       98.9%\      Yes                                           DNA sequencing, IHC                                Patients (China)                         HBV-associated HCC.\                                                                                                                                               \[[@B63-cells-09-00749]\]
                                                                       85/275                    1/85        84/85                                                                                                                                                 Correlated with age, not with HBV status.\                                                                                                                         
                                                                                                                                                                                                                                                                   Found in 4/7 preneoplastic lesions (HBV-associated HCC).                                                                                                           

  HCC                                                                  65.4%\                    3%\         97%\        Yes                                           DNA sequencing                                     Patients (Japan)                         Associated with older age.\                                                                                                                                        \[[@B122-cells-09-00749]\]
                                                                       68/104                    2/68        66/68                                                                                                                                                 Associated with shorter OS and DFS.\                                                                                                                               
                                                                                                                                                                                                                                                                   Associated with HCV infection and excluded from HBV+ HCC.                                                                                                          

  HCC                                                                  58.6%\                    6.1%\       92.7%\      Yes\                                          DNA sequencing, qRT-PCR                            Patients (French)                        Detected in cirrhotic preneoplastic macronodules (25%) and cirrhotic adenomas (44%), at last step of malignant transformation into HCC.\                           \[[@B62-cells-09-00749]\]
                                                                       179/305                   11/179      166/179     2--10-fold                                                                                                                                Absent from HBV-associated tumors 2/179 (1%) −146 C\>T.                                                                                                            

  HCC                                                                  29.3%\                    5.3%\       94.7%\      No                                            DNA sequencing, qRT-PCR                                                                     Associated with older age.\                                                                                                                                        \[[@B96-cells-09-00749]\]
                                                                       57/195                    3/57        54/57                                                                                                                                                 No impact on overall survival.\                                                                                                                                    
                                                                                                                                                                                                                                                                   Excluded from HBV-associated HCC.\                                                                                                                                 
                                                                                                                                                                                                                                                                   Higher frequency in HCV-associated HCC.                                                                                                                            

  HCC                                                                  54%\                      4.3%\       93%\        N/A                                           DNA sequencing                                     Patients (Japan, US-European ancestry)   −57 A\>C mutation detected in 1.6%.\                                                                                                                               \[[@B121-cells-09-00749]\]
                                                                       254/469                   11/254      236/254                                                                                                                                               Present in 37% HBV-associated HCC but mutually exclusive with HBV sequence integration.\                                                                           
                                                                                                                                                                                                                                                                   Mutually exclusive with *TERT* CNV and *ATRX* mutations.\                                                                                                          
                                                                                                                                                                                                                                                                   Associated with HCV infection (64% or *TERTp* mutations).\                                                                                                         
                                                                                                                                                                                                                                                                   Associated with Wnt pathway mutations.                                                                                                                             

  HCC                                                                  60%\                      11.1%\      88.9%\      N/A                                           DNA sequencing                                     Cell lines                                                                                                                                                                                                  \[[@B97-cells-09-00749]\]
                                                                       9/15                      1/9         8/9                                                                                                                                                                                                                                                                                                                      

  Total HCC                                                            770/1634\                 39/770\     722/770\                                                                                                                                                                                                                                                                                                                 
                                                                       (47.1%)                   (5%)        (93.7%)                                                                                                                                                                                                                                                                                                                  

  Cervical                                                                                                                                                                                                                                                                                                                                                                                                                            

  Cervical SCC                                                         21.8%\                    31.8%\      45.5%\      Yes                                           qRT-PCR                                            Patients (Italian women)                                                                                                                                                                                    \[[@B37-cells-09-00749]\]
                                                                       22/101                    7/22        10/22                                                                                                                                                                                                                                                                                                                    

  Cervical SCC                                                         21.4%\                    26.7%\      73.3%\      N/A                                           DNA sequencing, Association with clinical status   Patients (Indian women)                  75% *TERTp* mutations in HPV-negative samples.\                                                                                                                    \[[@B36-cells-09-00749]\]
                                                                       30/140                    8/30        22/30                                                                                                                                                 −124 C\>T 6/22 were TT homozygous.\                                                                                                                                
                                                                                                                                                                                                                                                                   −146 C\>T 2/8 were TT homozygous.                                                                                                                                  

  Cervical SCC                                                         4.5%\                     100%\       0%\         N/A                                           DNA sequencing                                     Patients\                                1 patient with −125 C\>A mutation.                                                                                                                                 
                                                                       1/22                      1/1         0/1                                                                                                          (US American)                                                                                                                                                                                               

  Total Cervical SCC                                                   53/263\                   16/53\      32/53\                                                                                                                                                                                                                                                                                                                   \[[@B77-cells-09-00749]\]
                                                                       (20.1%)                   (30.2%)     (60.4%)                                                                                                                                                                                                                                                                                                                  

  Head and Neck Squamous Cell Carcinoma (HNSCC)                                                                                                                                                                                                                                                                                                                                                                                       

  HNSCC                                                                31.7%\                    30.8%\      69.2%\      N/A                                           DNA sequencing                                     Patients (Indian women)                  Association with clinical status.                                                                                                                                  \[[@B36-cells-09-00749]\]
                                                                       13/41                     4/13        9/13                                                                                                                                                                                                                                                                                                                     

  HNSCC                                                                17%\                      16.7%\      83.3%\      N/A                                           DNA sequencing                                     Patients\                                11/12 HNSCC with *TERTp* mutations were in the oral tongue, and 11/23 (47.8%) of HNSCC of the oral tongue harbored *TERTp* mutations.                              \[[@B77-cells-09-00749]\]
                                                                       12/70                     2/12        10/12                                                                                                        (US American)                                                                                                                                                                                               

  Total HNSCC                                                          25/111\                   6/25\       19/25\                                                                                                                                                                                                                                                                                                                   
                                                                       (22.5%)                   (24%)       (76%)                                                                                                                                                                                                                                                                                                                    

  Ovarian cancer                                                                                                                                                                                                                                                                                                                                                                                                                      

  Ovarian clear cell carcinoma                                         15%\                      0%\         10%\        N/A                                           DNA sequencing                                     Patients\                                1 patient with −124 C\>A mutation.                                                                                                                                 \[[@B77-cells-09-00749]\]
                                                                       3/20                      0/3         2/3                                                                                                          (US American)                                                                                                                                                                                               

  Ovarian clear cell carcinoma                                         16.5%\                    8.1%\       91.9%\      N/A                                           DNA sequencing,\                                   Patients                                 No link with survival or age.\                                                                                                                                     \[[@B132-cells-09-00749]\]
                                                                       37/233                    3/37        34/37                                                     IHC, telomere length evaluation                                                             *TERTp* mutations tended to be mutually exclusive with loss of ARID1A protein expression and PIK3CA mutation.                                                      

  Ovarian clear cell carcinoma                                         30%\                      0%\         100%\       Yes                                           qRT-PCR                                            Cell lines                                                                                                                                                                                                  \[[@B132-cells-09-00749]\]
                                                                       3/10                      0/3         3/3                                                                                                                                                                                                                                                                                                                      

  Total ovarian clear cell carcinoma                                   43/263\                   3/43\       39/43\                                                                                                                                                                                                                                                                                                                   
                                                                       (16.3%)                   (6.9%)      (90.7%)                                                                                                                                                                                                                                                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N/A: not assessed; \*: data not available. TERT: telomerase reverse transcriptase; GBM: glioblastoma multiforme; SCC: squamous cell carcinoma; HNSCC: head and neck squamous cell carcinoma; HCC: hepatocellular carcinoma; GI: gastrointestinal; UC: urothelial cancer; MPC: micropapillary carcinoma; HPV: Human papilloma virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus; PTC: papillary thyroid cancer; FTC: follicular thyroid cancer; ATC: anaplastic thyroid cancer.
